Bacterial  ||| S:0 E:10 ||| JJ
genomics  ||| S:10 E:19 ||| NN
and  ||| S:19 E:23 ||| CC
metagenomics ||| S:23 E:35 ||| NNS
:  ||| S:35 E:37 ||| :
clinical  ||| S:37 E:46 ||| JJ
applications  ||| S:46 E:59 ||| NNS
and  ||| S:59 E:63 ||| CC
medical  ||| S:63 E:71 ||| JJ
relevance  ||| S:71 E:81 ||| NN
New  ||| S:81 E:85 ||| NNP
sequencing  ||| S:85 E:96 ||| NN
technologies  ||| S:96 E:109 ||| NNS
provide  ||| S:109 E:117 ||| VBP
in  ||| S:117 E:120 ||| IN
a  ||| S:120 E:122 ||| DT
short  ||| S:122 E:128 ||| JJ
time  ||| S:128 E:133 ||| NN
and  ||| S:133 E:137 ||| CC
at  ||| S:137 E:140 ||| IN
low  ||| S:140 E:144 ||| JJ
cost  ||| S:144 E:149 ||| NN
high  ||| S:149 E:154 ||| JJ
amount  ||| S:154 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
genomic  ||| S:164 E:172 ||| JJ
sequences  ||| S:172 E:182 ||| JJ
useful  ||| S:182 E:189 ||| JJ
for  ||| S:189 E:193 ||| IN
applications  ||| S:193 E:206 ||| NNS
such  ||| S:206 E:211 ||| JJ
as ||| S:211 E:213 ||| IN
:  ||| S:213 E:215 ||| :
a ||| S:215 E:216 ||| LS
)  ||| S:216 E:218 ||| -RRB-
development  ||| S:218 E:230 ||| NN
of  ||| S:230 E:233 ||| IN
diagnostic  ||| S:233 E:244 ||| JJ
PCRs  ||| S:244 E:249 ||| JJ
and ||| S:249 E:252 ||| CC
/ ||| S:252 E:253 ||| NNP
or  ||| S:253 E:256 ||| CC
serological  ||| S:256 E:268 ||| JJ
tests ||| S:268 E:273 ||| NNS
;  ||| S:273 E:275 ||| :
b ||| S:275 E:276 ||| LS
)  ||| S:276 E:278 ||| -RRB-
detection  ||| S:278 E:288 ||| NN
of  ||| S:288 E:291 ||| IN
virulence  ||| S:291 E:301 ||| JJ
factors  ||| S:301 E:309 ||| NNS
( ||| S:309 E:310 ||| -LRB-
virulome ||| S:310 E:318 ||| LS
)  ||| S:318 E:320 ||| -RRB-
or  ||| S:320 E:323 ||| CC
genes ||| S:323 E:328 ||| NNS
/ ||| S:328 E:329 ||| VBP
SNPs  ||| S:329 E:334 ||| JJ
associated  ||| S:334 E:345 ||| VBN
with  ||| S:345 E:350 ||| IN
resistance  ||| S:350 E:361 ||| NN
to  ||| S:361 E:364 ||| TO
antibiotics  ||| S:364 E:376 ||| VB
( ||| S:376 E:377 ||| -LRB-
resistome ||| S:377 E:386 ||| LS
)  ||| S:386 E:388 ||| -RRB-
and  ||| S:388 E:392 ||| CC
c ||| S:392 E:393 ||| LS
)  ||| S:393 E:395 ||| -RRB-
investigation  ||| S:395 E:409 ||| NN
of  ||| S:409 E:412 ||| IN
transmission  ||| S:412 E:425 ||| NN
and  ||| S:425 E:429 ||| CC
dissemination  ||| S:429 E:443 ||| NN
of  ||| S:443 E:446 ||| IN
bacterial  ||| S:446 E:456 ||| JJ
pathogens ||| S:456 E:465 ||| NN
.  ||| S:465 E:467 ||| .
Thus ||| S:467 E:471 ||| RB
,  ||| S:471 E:473 ||| ,
bacterial  ||| S:473 E:483 ||| JJ
genomics  ||| S:483 E:492 ||| NN
of  ||| S:492 E:495 ||| IN
medical  ||| S:495 E:503 ||| JJ
importance  ||| S:503 E:514 ||| NN
is  ||| S:514 E:517 ||| VBZ
useful  ||| S:517 E:524 ||| JJ
to  ||| S:524 E:527 ||| TO
clinical  ||| S:527 E:536 ||| JJ
microbiologists ||| S:536 E:551 ||| NN
,  ||| S:551 E:553 ||| ,
to  ||| S:553 E:556 ||| TO
infectious  ||| S:556 E:567 ||| JJ
diseases  ||| S:567 E:576 ||| NNS
specialists  ||| S:576 E:588 ||| NNS
as  ||| S:588 E:591 ||| IN
well  ||| S:591 E:596 ||| RB
as  ||| S:596 E:599 ||| RB
to  ||| S:599 E:602 ||| TO
epidemiologists ||| S:602 E:617 ||| VB
.  ||| S:617 E:619 ||| .
Determining  ||| S:619 E:631 ||| VBG
the  ||| S:631 E:635 ||| DT
microbial  ||| S:635 E:645 ||| JJ
composition  ||| S:645 E:657 ||| NN
of  ||| S:657 E:660 ||| IN
a  ||| S:660 E:662 ||| DT
sample  ||| S:662 E:669 ||| NN
by  ||| S:669 E:672 ||| IN
metagenomics  ||| S:672 E:685 ||| NN
is  ||| S:685 E:688 ||| VBZ
another  ||| S:688 E:696 ||| DT
application  ||| S:696 E:708 ||| NN
of  ||| S:708 E:711 ||| IN
new  ||| S:711 E:715 ||| JJ
sequencing  ||| S:715 E:726 ||| JJ
technologies ||| S:726 E:738 ||| NNS
,  ||| S:738 E:740 ||| ,
useful  ||| S:740 E:747 ||| JJ
to  ||| S:747 E:750 ||| TO
understand  ||| S:750 E:761 ||| VB
the  ||| S:761 E:765 ||| DT
impact  ||| S:765 E:772 ||| NN
of  ||| S:772 E:775 ||| IN
bacteria  ||| S:775 E:784 ||| NNS
on  ||| S:784 E:787 ||| IN
various  ||| S:787 E:795 ||| JJ
non-infectious  ||| S:795 E:810 ||| JJ
diseases  ||| S:810 E:819 ||| NNS
such  ||| S:819 E:824 ||| JJ
as  ||| S:824 E:827 ||| IN
obesity ||| S:827 E:834 ||| NN
,  ||| S:834 E:836 ||| ,
asthma ||| S:836 E:842 ||| NN
,  ||| S:842 E:844 ||| ,
or  ||| S:844 E:847 ||| CC
diabetes ||| S:847 E:855 ||| NN
.  ||| S:855 E:857 ||| .
Genomics  ||| S:857 E:866 ||| NNP
and  ||| S:866 E:870 ||| CC
metagenomics  ||| S:870 E:883 ||| NNS
will  ||| S:883 E:888 ||| MD
likely  ||| S:888 E:895 ||| RB
become  ||| S:895 E:902 ||| VB
a  ||| S:902 E:904 ||| DT
specialized  ||| S:904 E:916 ||| JJ
diagnostic  ||| S:916 E:927 ||| JJ
analysis ||| S:927 E:935 ||| NN
.  ||| S:935 E:937 ||| .
